TD Waterhouse Canada Inc. Reduces Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

TD Waterhouse Canada Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 48.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,109 shares of the medical equipment provider’s stock after selling 5,766 shares during the period. TD Waterhouse Canada Inc.’s holdings in Zimmer Biomet were worth $514,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ZBH. DV Equities LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth $25,000. Tacita Capital Inc bought a new position in Zimmer Biomet in the second quarter valued at about $26,000. Ancora Advisors LLC bought a new position in Zimmer Biomet in the second quarter valued at about $29,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet in the fourth quarter worth about $30,000. Finally, Gen Wealth Partners Inc purchased a new position in Zimmer Biomet in the fourth quarter worth about $31,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $92.30 on Friday. The firm has a fifty day simple moving average of $95.42 and a two-hundred day simple moving average of $91.51. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $106.88. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $17.61 billion, a P/E ratio of 22.46, a PEG ratio of 1.79 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm earned $2.07 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. UBS Group restated a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.